#11377. Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value

August 2026publication date
Proposal available till 12-05-2025
4 total number of authors per manuscript0 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Health (social science);
Health Policy;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2350 $1200 $1050 $900 $
Contract №11377.1 Contract №11377.2 Contract №11377.3 Contract №11377.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

More details about the manuscript: Science Citation Index Expanded or/and Social Sciences Citation Index
Abstract:
This article explores recent debates on innovation in the drug sector, focusing on the ways in which the articulation of use value and exchange value operates in the hegemonic form of pharmaceutical capitalism. Taking the category ‘crisis of innovation’ as an entry point and engaging with the economics literature in which it has been discussed for nearly twenty years, this paper uses the vast historiography of post-WWII pharmacy to propose a critical historical understanding of the crisis. It argues that the features to which the crisis discourses point originate in the long-term contradictions between use value and exchange that affect the dominant regime of pharmaceutical innovation, i.e., the screening regime of research and development. The last section of the paper discusses the theoretical implications of this hypothesis.
Keywords:
Bio-capital; Crisis of innovation; Expertise; Scientific marketing; Screening; Value

Contacts :
0